Radiopharmaceutical firm Ion Beam Applications (IBA) of Louvain-la-Neuve, Belgium, has received clearance from the U.S. Food and Drug Administration (FDA) for its pencil-beam scanning treatment option for proton therapy.
IBA developed the pencil-beam scanning (PBS) technology in collaboration with Massachusetts General Hospital in Boston to allow for enhanced dose delivery.
The PBS delivery method uses a proton beam that is actively scanned throughout the target tumor volume.
Related Reading
IBA opens Dallas PET facility, December 17, 2008
IBA responds to FDA warning letter, December 11, 2008
IBA opens production center in Dallas, December 2, 2008
IBA signs deal with Biotech Cyclotron, December 1, 2008
IBA's interim Q3 report shows mixed results, November 19, 2008
Copyright © 2008 AuntMinnie.com
